| Naslov: | Oral treatment with etoposide in small cell lung cancer - dilemmas and solution |
|---|
| Avtorji: | ID Režonja, Renata (Avtor)
ID Knez, Lea (Avtor)
ID Čufer, Tanja (Avtor)
ID Mrhar, Aleš (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (465,72 KB)
MD5: 45DAC2701B0E5B719E59F3BCAFAA9FDD
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.02 - Pregledni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | Background. Etoposide is a chemotherapeutic agent, widely used for the treatment of various malignancies, including small cell lung cancer (SCLC), an aggressive disease with poor prognosis. Oral etoposide administration exhibits advantages for the quality of life of the patient as well as economic benefits. However, widespread use of oral etoposide is limited by incomplete and variable bioavailability. Variability in bioavailability was observed both within and between patients. This suggests that some patients may experience suboptimal tumor cytotoxicity, whereas other patients may be atrisk for excess toxicity. Conclusions. The article highlights dilemmas as well as solutions regarding oral treatment with etoposide by presenting and analyzing relevant literature data. Numerous studies have shown that bioavailability of etoposide is influenced by genetic, physiological and environmental factors. Several strategies were explored to improve bioavailability and to reduce pharmacokinetic variability of oral etoposide, including desired and undesired drug interactions (e.g. with ketoconazole), development of suitable drug delivery systems, use of more water-soluble prodrug of etoposide, and influence on gastric emptying. In addition to genotype-based dose administration, etoposide is suitable for pharmacokinetically guided dosing, which enables dose adjustments in individual patient. Further, it is established that oral and intravenous schedules of etoposide in SCLC patients do not result in significant differences in treatment outcome, while results of toxicity are inconclusive. To conclude, the main message of the article is that better prediction of the pharmacokinetics of oral etoposide may encourage its wider use in routine clinical practice. |
|---|
| Ključne besede: | oral etoposide, bioavailability, pharmacokinetic variability, small cell lung cancer, treatment |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 01.03.2013 |
|---|
| Založnik: | Association of Radiology and Oncology |
|---|
| Leto izida: | 2013 |
|---|
| Št. strani: | str. 1-13, I |
|---|
| Številčenje: | Vol. 47, no. 1 |
|---|
| Izvor: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-18543  |
|---|
| UDK: | 615.015+616-006-08 |
|---|
| ISSN pri članku: | 1318-2099 |
|---|
| COBISS.SI-ID: | 3405937 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Datum objave v DiRROS: | 22.03.2024 |
|---|
| Število ogledov: | 93 |
|---|
| Število prenosov: | 32 |
|---|
| Metapodatki: |     |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
